Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Thomas W, Littlejohn"'
Autor:
Thomas W. Littlejohn, Maureen Kobe, Naitee Ting, Joel M. Neutel, George L. Bakris, Ludwin Ley, Arya M. Sharma
Publikováno v:
Clinical Therapeutics. 34:537-551
Hypertensive patients with diabetes often require combination therapy to achieve a blood pressure (BP) goal, and evidence suggests that time to BP goal is crucial to decrease cardiovascular risk.The aim of the study was to investigate whether the sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d85d541a10214265d3c37edbaf5285
https://doi.org/10.1016/j.clinthera.2012.02.004
https://doi.org/10.1016/j.clinthera.2012.02.004
Autor:
Hayes M. Dansky, Patrice H. Gibbons, Yale B. Mitchel, Thomas W. Littlejohn, James M. McKenney, Sherry Liu, Christine McCrary Sisk, Diane Tribble, Daniel M. Bloomfield
Publikováno v:
American Heart Journal. 162:708-716
This report describes the lipid and safety data collected during an off-drug period that followed 8 weeks of treatment with the cholesteryl ester transfer protein inhibitor, anacetrapib (ANA). A total of 589 patients with primary hypercholesterolemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a5d10563644741a864bed2417123de
https://doi.org/10.1016/j.ahj.2011.07.010
https://doi.org/10.1016/j.ahj.2011.07.010
Autor:
Brian K. Roberts, Thomas W. Littlejohn, Yun-Jung Choi, David B. Karpf, Ronald M. Krauss, Sue Naim, Boris Kerzner, Wang Xueyan, Harold E. Bays, Sherwyn Schwartz
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 96:2889-2897
Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone.The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575284ca63b8af6323cc013411a8de47
https://doi.org/10.1210/jc.2011-1061
https://doi.org/10.1210/jc.2011-1061
Autor:
Giuseppe Mancia, Willie Oigman, Mary Seeber, Helmut Schumacher, Claudio R. Majul, William B. White, Rafael Olvera, Thomas W. Littlejohn
Publikováno v:
Blood Pressure Monitoring. 15:205-212
Evaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d709b2c2178e80faee08382099c0970b
https://doi.org/10.1097/mbp.0b013e32833c5722
https://doi.org/10.1097/mbp.0b013e32833c5722
Autor:
Thomas W, Littlejohn, Claudio R, Majul, Rafael, Olvera, Mary, Seeber, Maureen, Kobe, Robert, Guthrie, Wille, Oigman, S, Yates
Publikováno v:
J Clin Hypertens (Greenwich)
This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9e55ad89e46031c7fcac6e278ef9ce
https://doi.org/10.1111/j.1751-7176.2009.00098.x
https://doi.org/10.1111/j.1751-7176.2009.00098.x
Autor:
Thomas W. Littlejohn, Karine Lheritier, Dominik Richard, Thomas M. MacDonald, Gerhard Krammer, Rosemary Rebuli, Jean-Yves Reginster
Publikováno v:
Journal of Hypertension. 26:1695-1702
Objectives Nonsteroidal anti-inflammatory drugs vary in their impact on blood pressure and the effect of lumiracoxib 100 mg once daily has not been studied previously. To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81076520d41476fff41931d2beb723a8
https://doi.org/10.1097/hjh.0b013e328302c9fe
https://doi.org/10.1097/hjh.0b013e328302c9fe
Autor:
Paulette A. Lyle, Peter U. Feig, Gilbert W. Gleim, Joseph Rubino, Hongyan Zhang, Beth Soffer, Shahnaz Shahinfar, Thomas W. Littlejohn
Publikováno v:
Clinical Therapeutics. 28:1639-1648
Because patients with hypertension may require1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications.This study evaluated the effect of adding low-dose hydrochlorothiazi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d23cfbfb39c51179d8455c314975a39
https://doi.org/10.1016/j.clinthera.2006.10.014
https://doi.org/10.1016/j.clinthera.2006.10.014
Autor:
Evan A. Stein, David Kallend, Karen Smith, James Shepherd, Christopher J. Packard, James Walker, Thomas W. Littlejohn, James W. Blasetto
Publikováno v:
Current Medical Research and Opinion. 20:1571-1578
To evaluate the efficacy and safety of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy (HRT) in a randomized, double-blind, placebo-controlled trial.After a 6-week dietary lead-in period, 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f2d22f79e29320bb77a322925585681
https://doi.org/10.1185/030079904x4167
https://doi.org/10.1185/030079904x4167
Autor:
Helmut G. Schrott, Thomas W. Littlejohn, Richard McLain, Robert H. Knopp, Harold E. Bays, Peter H. Jones, Donald M. Black, Anita Gmerek Fereshetian
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 3:119-123
Background: Coronary heart disease (CHD) is the number one cause of death in Western societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer ides (TG) increase the risk for CHD. 3-Hydroxy-3-methylglutaryl conenzym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6142c63b42386d351c608d072695c56d
https://doi.org/10.1177/107424849800300204
https://doi.org/10.1177/107424849800300204
Autor:
Michelle M Wolf, Thomas W. Littlejohn, Kenneth J. Tack, Gail B. Mailloux, Constance H. Keyserling
Publikováno v:
Clinical Therapeutics. 20:244-256
Because of increasing resistance to older antimicrobial agents, newer drugs need to be evaluated for the treatment of skin and skin-structure infections (SSSIs). This double-masked, randomized, comparative, multicenter study enrolled patients aged 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5892f8bf094a887149ef490242b31961
https://doi.org/10.1016/s0149-2918(98)80088-x
https://doi.org/10.1016/s0149-2918(98)80088-x